US6569679B1
(en)
*
|
1988-03-21 |
2003-05-27 |
Chiron Corporation |
Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
|
US5997859A
(en)
*
|
1988-03-21 |
1999-12-07 |
Chiron Corporation |
Method for treating a metastatic carcinoma using a conditionally lethal gene
|
US6605712B1
(en)
*
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
US5631236A
(en)
|
1993-08-26 |
1997-05-20 |
Baylor College Of Medicine |
Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
|
KR960703172A
(ko)
*
|
1993-11-18 |
1996-06-19 |
스티븐 제이. 멘토 |
조건적으로 치사적인 유전자를 활용하기 위한 조성물 및 방법(Compositions and methods for utilizing conditionally lethal genes)
|
FR2712602B1
(fr)
*
|
1993-11-18 |
1996-02-09 |
Centre Nat Rech Scient |
Virus recombinants, préparation et utilisation en thérapie génique.
|
US5670347A
(en)
|
1994-05-11 |
1997-09-23 |
Amba Biosciences Llc |
Peptide-mediated gene transfer
|
US6204052B1
(en)
|
1994-08-16 |
2001-03-20 |
Introgene B.V. |
Adenoviral vectors with reduced TNF response and partial E3 region deletion
|
US5688773A
(en)
*
|
1994-08-17 |
1997-11-18 |
The General Hospital Corporation |
Method of selectively destroying neoplastic cells
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
US6638762B1
(en)
*
|
1994-11-28 |
2003-10-28 |
Genetic Therapy, Inc. |
Tissue-vectors specific replication and gene expression
|
WO1996026743A1
(en)
*
|
1995-03-01 |
1996-09-06 |
Human Gene Therapy Research Institute |
Radiation enhanced gene therapy for treatment of tumors
|
ES2200061T3
(es)
*
|
1995-03-28 |
2004-03-01 |
Thomas Jefferson University |
Celulas estromales aisladas y procedimientos para el uso de las mismas.
|
US6974571B2
(en)
|
1995-03-28 |
2005-12-13 |
Thomas Jefferson University |
Isolated stromal cells and methods of using the same
|
WO1996035455A1
(en)
*
|
1995-05-11 |
1996-11-14 |
Genetic Therapy, Inc. |
Gene therapy through transduction of oral epithelial cells
|
US6190657B1
(en)
|
1995-06-07 |
2001-02-20 |
Yale University |
Vectors for the diagnosis and treatment of solid tumors including melanoma
|
US20020068049A1
(en)
*
|
1998-09-10 |
2002-06-06 |
Henderson Daniel R. |
Tissue specific adenoviral vectors
|
US6392069B2
(en)
|
1996-01-08 |
2002-05-21 |
Canji, Inc. |
Compositions for enhancing delivery of nucleic acids to cells
|
US5789244A
(en)
*
|
1996-01-08 |
1998-08-04 |
Canji, Inc. |
Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
|
US20040014709A1
(en)
*
|
1996-01-08 |
2004-01-22 |
Canji, Inc. |
Methods and compositions for interferon therapy
|
US7002027B1
(en)
|
1996-01-08 |
2006-02-21 |
Canji, Inc. |
Compositions and methods for therapeutic use
|
US5998384A
(en)
*
|
1996-01-26 |
1999-12-07 |
Hisamitsu Pharmaceutical Co., Inc. |
Endoscopic administration of an HSV-tk gene to treat digestive organ cancer
|
DE19605279A1
(de)
*
|
1996-02-13 |
1997-08-14 |
Hoechst Ag |
Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
|
US5948681A
(en)
*
|
1996-08-14 |
1999-09-07 |
Children's Hospital Of Philadelphia |
Non-viral vehicles for use in gene transfer
|
US6610839B1
(en)
|
1997-08-14 |
2003-08-26 |
Geron Corporation |
Promoter for telomerase reverse transcriptase
|
US6777203B1
(en)
|
1997-11-19 |
2004-08-17 |
Geron Corporation |
Telomerase promoter driving expression of therapeutic gene sequences
|
SK50699A3
(en)
*
|
1996-10-18 |
2000-05-16 |
Canji Inc |
Methods and compositions for delivery and expression of interferon-'alpha' nucleic acids
|
EP0931156A2
(de)
*
|
1996-10-18 |
1999-07-28 |
Valentis Inc. |
Genexpressions- und transfersysteme und deren verwendungen
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US5772993A
(en)
*
|
1997-01-21 |
1998-06-30 |
The University Of Virginia Patent Foundation |
Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues
|
WO1998046264A1
(en)
|
1997-04-11 |
1998-10-22 |
G.D. Searle & Co. |
Antagonistic anti-avb3 integrin antibodies
|
US6193968B1
(en)
|
1997-04-11 |
2001-02-27 |
The Burnham Institute |
Methods for using anti-αvβ3 integrin antibody
|
US6096718A
(en)
*
|
1997-06-05 |
2000-08-01 |
Gene Targeting Corp. |
Tissue specific adenovirus vectors for breast cancer treatment
|
US6207648B1
(en)
|
1997-07-24 |
2001-03-27 |
Trustees Of Boston University |
Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
US6080849A
(en)
|
1997-09-10 |
2000-06-27 |
Vion Pharmaceuticals, Inc. |
Genetically modified tumor-targeted bacteria with reduced virulence
|
US7378244B2
(en)
|
1997-10-01 |
2008-05-27 |
Geron Corporation |
Telomerase promoters sequences for screening telomerase modulators
|
US7041654B2
(en)
|
1997-10-03 |
2006-05-09 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Methods and compositions for inducing tumor-specific cytotoxicity
|
US6087164A
(en)
|
1997-10-03 |
2000-07-11 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Methods and compositions for inducing tumor-specific cytotoxicity
|
AU1085099A
(en)
|
1997-10-16 |
1999-05-03 |
Children's Medical Center Corporation |
Thymosin beta15 promoter and use thereof
|
EP1900818A3
(de)
|
1997-11-06 |
2008-06-11 |
Novartis Vaccines and Diagnostics S.r.l. |
Neissersche Antigene
|
AU1979599A
(en)
|
1998-01-14 |
1999-08-02 |
Chiron S.P.A. |
(neisseria meningitidis) antigens
|
AU749881B2
(en)
*
|
1998-02-03 |
2002-07-04 |
Inex Pharmaceuticals Corporation |
Systemic delivery of serum stable plasmid lipid particles for cancer therapy
|
US6410328B1
(en)
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
EP1053317B1
(de)
*
|
1998-02-13 |
2006-11-02 |
Köster, Hubert |
Verwendung von ribozymen zur bestimmung der funktion von genen
|
FR2777570A1
(fr)
*
|
1998-04-17 |
1999-10-22 |
Transgene Sa |
Mutant ayant une activite phosphoribosyl transferase
|
EP2261356A3
(de)
|
1998-05-01 |
2012-01-04 |
Novartis Vaccines and Diagnostics, Inc. |
Antigene und Zusammensetzungen gegen Neisseria meningitidis
|
US5973119A
(en)
*
|
1998-06-05 |
1999-10-26 |
Amgen Inc. |
Cyclin E genes and proteins
|
US20030017138A1
(en)
*
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
US6344541B1
(en)
*
|
1998-09-25 |
2002-02-05 |
Amgen Inc. |
DKR polypeptides
|
US6552005B1
(en)
*
|
1998-09-29 |
2003-04-22 |
Uab Research Foundation |
Molecular chemotherapy enhancement of radiotherapy
|
GB9824437D0
(en)
|
1998-11-06 |
1999-01-06 |
Ylo Herttuala Seppo |
Gene therapy
|
US6929946B1
(en)
*
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
WO2000034497A2
(en)
|
1998-12-09 |
2000-06-15 |
The General Hospital Corporation |
Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
|
US6869936B1
(en)
|
1999-03-04 |
2005-03-22 |
Crucell Holland B.V. |
Means and methods for fibroblast-like or macrophage-like cell transduction
|
WO2000058479A1
(en)
|
1999-03-26 |
2000-10-05 |
Amgen Inc. |
Beta secretase genes and polypeptides
|
US6677155B1
(en)
|
1999-04-22 |
2004-01-13 |
The General Hospital Corporation |
Triple hybrid amplicon vector systems to generate retroviral packaging lines
|
CA2372235A1
(en)
|
1999-04-30 |
2000-11-09 |
Rino Rappuoli |
Conserved neisserial antigens
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
EP1185627A2
(de)
*
|
1999-06-01 |
2002-03-13 |
Cornell Research Foundation, Inc. |
Aktivierung von dendritischen zellen zur verstärkung der immunität
|
WO2000072686A1
(en)
*
|
1999-06-02 |
2000-12-07 |
Cell Genesys, Inc. |
Regulation of systemic immune responses utilizing cytokines and antigens
|
US6673602B1
(en)
|
1999-06-11 |
2004-01-06 |
The General Hospital Corporation |
Herpes simplex virus amplicon vector targeting system and method of using same
|
US7589069B1
(en)
*
|
1999-07-12 |
2009-09-15 |
Saint Louis University |
Replication-competent anti-cancer vectors
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
WO2001005229A1
(en)
|
1999-07-15 |
2001-01-25 |
The General Hospital Corporation |
Non-defective epstein-barr viral vector
|
US6770632B1
(en)
|
1999-07-16 |
2004-08-03 |
The General Hospital Corporation |
Folypolyglutamyl synthetase gene transfer to enhance antifolate
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US6900043B1
(en)
*
|
1999-09-21 |
2005-05-31 |
Amgen Inc. |
Phosphatases which activate map kinase pathways
|
CA2386806A1
(en)
*
|
1999-10-04 |
2001-04-12 |
Vion Pharmaceuticals, Inc. |
Non-invasive tumor imaging by tumor-targeted bacteria
|
US6962696B1
(en)
|
1999-10-04 |
2005-11-08 |
Vion Pharmaceuticals Inc. |
Compositions and methods for tumor-targeted delivery of effector molecules
|
GB9924981D0
(en)
*
|
1999-10-21 |
1999-12-22 |
Univ Manchester |
Gene therapy
|
US6716824B1
(en)
*
|
1999-10-22 |
2004-04-06 |
F. Charles Brunicardi |
Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
|
EP2975127A1
(de)
|
1999-10-29 |
2016-01-20 |
GlaxoSmithKline Biologicals SA |
Neisseria antigenpeptide
|
PT1248647E
(pt)
|
2000-01-17 |
2010-11-18 |
Novartis Vaccines & Diagnostics Srl |
Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
|
US20050239061A1
(en)
*
|
2000-03-01 |
2005-10-27 |
Marshall William S |
Identification and use of effectors and allosteric molecules for the alteration of gene expression
|
EP1263474A1
(de)
*
|
2000-03-08 |
2002-12-11 |
Neurosearch A/S |
Verfahren zur sensibilisierung von endothelzellen für medikamentenvorstufen
|
US6897020B2
(en)
|
2000-03-20 |
2005-05-24 |
Newlink Genetics Inc. |
Methods and compositions for elucidating relative protein expression levels in cells
|
US7514239B2
(en)
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
GB0008966D0
(en)
*
|
2000-04-13 |
2000-05-31 |
Imp College Innovations Ltd |
Vectors for gene therapy
|
US6331528B1
(en)
*
|
2000-04-25 |
2001-12-18 |
Ajinomoto Co., Inc. |
Method for treatment in gene therapy and use of guanine derivative therefor
|
EP2077279B1
(de)
|
2000-06-28 |
2012-09-05 |
Amgen Inc. |
Thymic Stromal Lymphopoietin Rezeptor Moleküle und Verwendungen davon
|
EP2189473A3
(de)
|
2000-10-27 |
2010-08-11 |
Novartis Vaccines and Diagnostics S.r.l. |
Nukleinsäure und Proteine von Gruppen A und B Streptokokken
|
AU2003222427B8
(en)
|
2000-11-17 |
2010-04-29 |
Vascular Biogenics Ltd. |
Promoters exhibiting endothelial cell specificity and methods of using same
|
US8071740B2
(en)
*
|
2000-11-17 |
2011-12-06 |
Vascular Biogenics Ltd. |
Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
|
WO2002042468A2
(en)
|
2000-11-27 |
2002-05-30 |
Geron Corporation |
Glycosyltransferase vectors for treating cancer
|
US6921665B2
(en)
*
|
2000-11-27 |
2005-07-26 |
Roslin Institute (Edinburgh) |
Selective antibody targeting of undifferentiated stem cells
|
US6576464B2
(en)
*
|
2000-11-27 |
2003-06-10 |
Geron Corporation |
Methods for providing differentiated stem cells
|
US20020107219A1
(en)
*
|
2000-12-05 |
2002-08-08 |
Curiel David T. |
Adenoviral vector containing cyclooxygenase-2 promoter and uses thereof
|
US6794376B2
(en)
*
|
2000-12-06 |
2004-09-21 |
William Beaumont Hospital |
Methods and compositions for enhancing diffusion of therapeutic agents through tissue
|
US7214515B2
(en)
*
|
2001-01-05 |
2007-05-08 |
The General Hospital Corporation |
Viral delivery system for infectious transfer of large genomic DNA inserts
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
CN1520303B
(zh)
*
|
2001-03-27 |
2013-04-24 |
纽约大学 |
利用基于α病毒且靶向高亲和性层粘连蛋白受体的载体进行肿瘤治疗
|
US20040242523A1
(en)
*
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
ES2380007T3
(es)
*
|
2001-04-06 |
2012-05-07 |
The University Of Chicago |
Inducción por agentes quimioterapéuticos de la actividad del promotor Egr-1 en la terapia génica
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
US8058248B2
(en)
*
|
2001-04-26 |
2011-11-15 |
The United States Of America As Represented By The Secretary Of Agriculture |
Foot and mouth disease virus vaccine comprising interferons
|
US20060159657A1
(en)
*
|
2001-06-14 |
2006-07-20 |
Macromed, Incorporated |
Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
|
US20030003074A1
(en)
*
|
2001-06-14 |
2003-01-02 |
Macromed, Inc. |
Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
|
US7015253B2
(en)
*
|
2001-07-10 |
2006-03-21 |
American Medical Systems, Inc. |
Regimen for treating prostate tissue and surgical kit for use in the regimen
|
US20140088177A1
(en)
*
|
2001-07-11 |
2014-03-27 |
University Of Miami |
Recombinant vsv for the treatment of tumor cells
|
AU2008201293B2
(en)
*
|
2001-07-11 |
2011-08-18 |
University Of Miami |
Recombinant VSV for the treatment of tumor cells
|
JP2004537305A
(ja)
*
|
2001-07-11 |
2004-12-16 |
ユニバーシティー オブ マイアミ |
腫瘍細胞の処置のための組換えvsv
|
US20030032597A1
(en)
*
|
2001-07-31 |
2003-02-13 |
Sebestyen Magdolna G. |
Targeting nucleic acids to a cellular nucleus
|
AU2002365070A1
(en)
*
|
2001-08-03 |
2003-06-30 |
Diversa Corporation |
P450 enzymes, nucleic acids encoding them and methods of making and using them
|
WO2003014140A1
(en)
*
|
2001-08-09 |
2003-02-20 |
Board Of Trustees Of The University Of Arkansas |
Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer
|
AU2002343901A1
(en)
|
2001-09-29 |
2003-04-14 |
Kim, Joo-Hang |
Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus
|
EP1442125A4
(de)
*
|
2001-10-04 |
2004-12-08 |
Carlos Estuard Aguilar-Cordova |
Chimäre virusvektoren für die gentherapie
|
AU2002337892A1
(en)
*
|
2001-10-18 |
2003-04-28 |
Aventis Pharmaceuticals Inc. |
Vectors for expressing multiple transgenes
|
MXPA04003514A
(es)
|
2001-10-19 |
2004-07-23 |
Vascular Biogenics Ltd |
Construcciones de polinucleotidos, composiciones farmaceuticas y metodos para reducir la regulacion dirigida de angionesis y terapia anticancer.
|
US20030086903A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
Therapeutic regimen for treating cancer
|
AU2002343739A1
(en)
*
|
2001-11-14 |
2003-05-26 |
Medlogic Global Limited |
Improved therapy for topical diseases
|
NZ546711A
(en)
|
2001-12-12 |
2008-06-30 |
Chiron Srl |
Immunisation against chlamydia trachomatis
|
WO2003049763A1
(en)
*
|
2001-12-12 |
2003-06-19 |
Fh Faulding & Co Limited |
Composition for the preservation of viruses
|
AU2003217693A1
(en)
*
|
2002-02-22 |
2003-09-09 |
Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
US7662924B2
(en)
*
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
US20040053836A1
(en)
*
|
2002-04-22 |
2004-03-18 |
Philipp Mayer-Kuckuk |
Method for modulating the production of a selected protein in vivo
|
CA2421269A1
(en)
|
2002-08-09 |
2004-02-09 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
US7977049B2
(en)
|
2002-08-09 |
2011-07-12 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
WO2004024895A2
(en)
*
|
2002-09-16 |
2004-03-25 |
Plexxikon, Inc. |
Crystal structure of pim-1 kinase
|
US20040052161A1
(en)
*
|
2002-09-17 |
2004-03-18 |
Steven Liao |
Mechanical clock having wireless manipulation and adjustment function
|
EP1572131B1
(de)
*
|
2002-10-08 |
2016-07-06 |
Immunomedics, Inc. |
Antikörper-therapie
|
US20050113324A1
(en)
*
|
2003-01-15 |
2005-05-26 |
Bondarev Igor E. |
Modulation of line-1 reverse transcriptase
|
US20050048573A1
(en)
*
|
2003-02-03 |
2005-03-03 |
Plexxikon, Inc. |
PDE5A crystal structure and uses
|
US20050170431A1
(en)
*
|
2003-02-28 |
2005-08-04 |
Plexxikon, Inc. |
PYK2 crystal structure and uses
|
US20040191873A1
(en)
*
|
2003-03-27 |
2004-09-30 |
Won-Bin Young |
Method for high throughput elucidation of transcriptional profiles and genome annotation
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
US20050079548A1
(en)
*
|
2003-07-07 |
2005-04-14 |
Plexxikon, Inc. |
Ligand development using PDE4B crystal structures
|
WO2005028624A2
(en)
*
|
2003-09-15 |
2005-03-31 |
Plexxikon, Inc. |
Molecular scaffolds for kinase ligand development
|
ES2340038T3
(es)
*
|
2003-11-14 |
2010-05-28 |
Genvec, Inc. |
Composicion farmaceutica para tratar cancer de pancreas localmente avanzado (cpla) no extirpable.
|
WO2005058368A1
(en)
*
|
2003-12-10 |
2005-06-30 |
Canji, Inc. |
Methods and compositions for treatment of interferon-resistant tumors
|
AU2004308299B2
(en)
*
|
2003-12-19 |
2011-11-24 |
Plexxikon, Inc. |
Compounds and methods for development of Ret modulators
|
US20070066641A1
(en)
*
|
2003-12-19 |
2007-03-22 |
Prabha Ibrahim |
Compounds and methods for development of RET modulators
|
GB0406215D0
(en)
|
2004-03-19 |
2004-04-21 |
Procure Therapeutics Ltd |
Prostate stem cell
|
DK1736541T3
(da)
|
2004-03-29 |
2013-05-06 |
Galpharma Co Ltd |
Nyt modificeret galectin 9-protein og anvendelse heraf
|
US7585859B2
(en)
*
|
2004-05-06 |
2009-09-08 |
Plexxikon, Inc. |
PDE4B inhibitors and uses therefor
|
ITMI20041032A1
(it)
*
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Compositi farmaceutici
|
EP1749098B1
(de)
|
2004-05-26 |
2010-12-15 |
Bayer Schering Pharma Aktiengesellschaft |
Chimäre adenoviren zur verwendung in der krebsbehandlung
|
US7498342B2
(en)
|
2004-06-17 |
2009-03-03 |
Plexxikon, Inc. |
Compounds modulating c-kit activity
|
GB0413702D0
(en)
|
2004-06-18 |
2004-07-21 |
Molmed Spa |
Thymidine kinase
|
WO2006009575A1
(en)
|
2004-06-22 |
2006-01-26 |
The Board Of Trustees Of The University Of Illinois |
METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA
|
GB0416487D0
(en)
*
|
2004-07-23 |
2004-08-25 |
Isis Innovation |
Modified virus
|
ES2364663T3
(es)
*
|
2004-08-12 |
2011-09-08 |
Cedars-Sinai Medical Center |
Terapia génica combinada para el tratamiento de gliomas macroscópicos.
|
DE602005024148D1
(de)
*
|
2004-08-25 |
2010-11-25 |
Univ Chicago |
Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
|
CA2583428A1
(en)
*
|
2004-09-03 |
2006-03-09 |
Plexxikon, Inc. |
Bicyclic heteroaryl pde4b inhibitors
|
DE102004054215A1
(de)
*
|
2004-11-10 |
2006-05-11 |
Merck Patent Gmbh |
Pyridopyrimidinonderivate
|
KR100747646B1
(ko)
|
2005-02-25 |
2007-08-08 |
연세대학교 산학협력단 |
데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
|
EP1868615A4
(de)
*
|
2005-03-25 |
2012-06-27 |
Alt Solutions Inc |
Telomerlängenmodulation in telomerase-positiven zellen und krebstherapie
|
MX2007014377A
(es)
|
2005-05-17 |
2008-02-06 |
Plexxikon Inc |
Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina.
|
CN104906105A
(zh)
*
|
2005-05-18 |
2015-09-16 |
Alt解决方案公司 |
为预防和治疗癌症对癌细胞中端粒长度的药理学调节
|
ATE518860T1
(de)
*
|
2005-06-22 |
2011-08-15 |
Plexxikon Inc |
Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
|
US7358489B2
(en)
*
|
2005-08-04 |
2008-04-15 |
Airware, Inc. |
Ultra low cost NDIR gas sensors
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
WO2008079909A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Pyrrolo [2,3-b] pyridines as kinase modulators
|
US7872018B2
(en)
|
2006-12-21 |
2011-01-18 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
PE20121126A1
(es)
*
|
2006-12-21 |
2012-08-24 |
Plexxikon Inc |
Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
|
JP5369336B2
(ja)
|
2007-01-02 |
2013-12-18 |
アクアビーム エルエルシー |
前立腺の疾患を治療するための侵襲性が最小である方法及びデバイス
|
US9232959B2
(en)
|
2007-01-02 |
2016-01-12 |
Aquabeam, Llc |
Multi fluid tissue resection methods and devices
|
US8883493B2
(en)
*
|
2007-01-30 |
2014-11-11 |
Cedars-Sinai Medical Center |
Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
|
WO2009012170A1
(en)
*
|
2007-07-13 |
2009-01-22 |
California Institute Of Technology |
Targeting the absence: homozygous dna deletions as signposts for cancer therapy
|
JP2010533729A
(ja)
|
2007-07-17 |
2010-10-28 |
プレキシコン,インコーポレーテッド |
キナーゼ調節のための化合物と方法、及びそのための適応
|
US8282918B2
(en)
*
|
2007-07-30 |
2012-10-09 |
University Of Iowa Research Foundation |
Polynucleotides encoding RPA4/RPA32 hybrid polypeptides
|
DE102007056488A1
(de)
*
|
2007-11-22 |
2009-07-23 |
Biontex Laboratories Gmbh |
Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
|
KR101164602B1
(ko)
|
2008-01-09 |
2012-07-10 |
주식회사 케이알바이오텍 |
배큘로바이러스?기반 백신
|
JP5506702B2
(ja)
|
2008-03-06 |
2014-05-28 |
アクアビーム エルエルシー |
流体流れ内を伝達される光学エネルギーによる組織切除および焼灼
|
US9181315B2
(en)
|
2009-01-08 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
WO2010083456A1
(en)
|
2009-01-15 |
2010-07-22 |
Imdaptive Inc. |
Adaptive immunity profiling and methods for generation of monoclonal antibodies
|
EP4123030A1
(de)
|
2009-03-02 |
2023-01-25 |
The Regents of the University of California |
Tumorselektive e1a- und e1b-mutanten
|
US9848904B2
(en)
|
2009-03-06 |
2017-12-26 |
Procept Biorobotics Corporation |
Tissue resection and treatment with shedding pulses
|
EP2408904B1
(de)
|
2009-03-20 |
2017-10-18 |
Mesoblast, Inc. |
Herstellung von umprogrammierten pluripotenten zellen
|
TWI404719B
(zh)
*
|
2009-04-03 |
2013-08-11 |
Hoffmann La Roche |
組合物及其用途
|
EP2248903A1
(de)
|
2009-04-29 |
2010-11-10 |
Universitat Autònoma De Barcelona |
Verfahren und Reagenzien zum effizienten und gezielten Gentransfer in Monozyten und Makrophagen
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
GB0916997D0
(en)
|
2009-09-28 |
2009-11-11 |
Ark Therapeutics Ltd |
Combination therapy
|
US20110112127A1
(en)
|
2009-11-06 |
2011-05-12 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
JP2013517772A
(ja)
|
2010-01-21 |
2013-05-20 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
遺伝子発見および標的確認を補助するための状況特異的遺伝子スクリーニングプラットフォーム
|
US9597379B1
(en)
|
2010-02-09 |
2017-03-21 |
David Gordon Bermudes |
Protease inhibitor combination with therapeutic proteins including antibodies
|
EP2571987B1
(de)
|
2010-05-21 |
2017-03-01 |
Peptimed, Inc. |
Reagenzien zur behandlung von krebs
|
WO2012064743A2
(en)
|
2010-11-08 |
2012-05-18 |
The Johns Hopkins University |
Methods for improving heart function
|
WO2012095548A2
(es)
|
2011-01-13 |
2012-07-19 |
Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) |
Compuestos para el tratamiento de enfermedades neurodegenerativas
|
EP2672967B1
(de)
|
2011-02-07 |
2018-10-17 |
Plexxikon Inc. |
Verbindungen und verfahren zur kinase-modulation und anzeigen dafür
|
TWI558702B
(zh)
|
2011-02-21 |
2016-11-21 |
普雷辛肯公司 |
醫藥活性物質的固態形式
|
BR112013029163A2
(pt)
|
2011-05-17 |
2017-01-31 |
Plexxikon Inc |
modulação quinase e indicações dos mesmos
|
KR101293620B1
(ko)
|
2011-08-19 |
2013-08-13 |
국립암센터 |
트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도
|
US8969519B2
(en)
|
2011-09-13 |
2015-03-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using FNDC5
|
US10378060B2
(en)
|
2011-10-14 |
2019-08-13 |
Dana-Farber Cancer Institute, Inc. |
ZNF365/ZFP365 biomarker predictive of anti-cancer response
|
US9404090B2
(en)
|
2011-11-24 |
2016-08-02 |
Viromed Co., Ltd. |
Adenovirus producing novel cell line and the use thereof
|
EP2819599B1
(de)
|
2012-02-29 |
2018-05-23 |
Procept Biorobotics Corporation |
Automatisierte bildgeführte geweberesektion und behandlung
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
US9259343B2
(en)
|
2012-07-06 |
2016-02-16 |
Newman Technologies LLC |
Device for mitigating plantar fasciitis
|
JP6403695B2
(ja)
|
2013-02-14 |
2018-10-10 |
プロセプト バイオロボティクス コーポレイション |
アクアアブレーションアクアビーム眼科手術方法および装置
|
CN109965976B
(zh)
|
2013-09-06 |
2022-05-31 |
普罗赛普特生物机器人公司 |
利用致脱脉冲的用于消融组织的装置
|
EP3831398A1
(de)
|
2013-10-25 |
2021-06-09 |
PsiOxus Therapeutics Limited |
Onkolytische adenoviren, die mit heterologen genen ausgestattet sind
|
WO2015066190A1
(en)
|
2013-10-29 |
2015-05-07 |
President And Fellows Of Harvard College |
Methods and compositions for inhibting oxidative stress
|
CA2944903A1
(en)
|
2014-04-24 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
BR112016031037B1
(pt)
|
2014-06-30 |
2023-02-07 |
Procept Biorobotics Corporation |
Aparelho para ablação de tecido vascular
|
EP3188662A4
(de)
|
2014-09-05 |
2018-05-23 |
Procept Biorobotics Corporation |
Arztkontrollierte geweberesektion mit integriertem behandlungsmapping von zielorganbildern
|
WO2016057367A1
(en)
|
2014-10-06 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
CN113230384A
(zh)
|
2014-10-09 |
2021-08-10 |
丹娜法伯癌症研究院 |
用于治疗免疫失调的多次-可变il-2剂量方案
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
CN104740681A
(zh)
*
|
2015-03-02 |
2015-07-01 |
吉林大学 |
一种聚乳酸-羟基乙酸/腺病毒复合纳米纤维支架材料、制备方法及其应用
|
US10948492B2
(en)
|
2015-03-06 |
2021-03-16 |
Dana-Farber Cancer Institute, Inc. |
PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
|
US10160755B2
(en)
|
2015-04-08 |
2018-12-25 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
EP3288573B1
(de)
|
2015-04-30 |
2020-02-12 |
Psioxus Therapeutics Limited |
Onkolytisches adenovirus das für ein b7 protein kodiert
|
WO2017019804A2
(en)
|
2015-07-28 |
2017-02-02 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
EP3362074B1
(de)
|
2015-10-16 |
2023-08-09 |
President and Fellows of Harvard College |
Pd-1-modulation in regulatorischen t-zellen zur regulierung von t-zelleffektorimmunreaktionen
|
AU2016343978A1
(en)
|
2015-10-29 |
2018-05-17 |
Dana-Farber Cancer Institute, Inc. |
Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids
|
CN108368110A
(zh)
|
2015-12-07 |
2018-08-03 |
普莱希科公司 |
用于激酶调节的化合物和方法以及其适应症
|
AU2016369485B2
(en)
|
2015-12-17 |
2024-02-01 |
Akamis Bio Limited |
Group B adenovirus encoding an anti-TCR-complex antibody or fragment
|
CN110753755B
(zh)
|
2016-03-21 |
2023-12-29 |
丹娜法伯癌症研究院 |
T细胞耗竭状态特异性基因表达调节子及其用途
|
US10183058B2
(en)
|
2016-06-17 |
2019-01-22 |
Nymox Corporation |
Method of preventing or reducing the progression of prostate cancer
|
US10172910B2
(en)
|
2016-07-28 |
2019-01-08 |
Nymox Corporation |
Method of preventing or reducing the incidence of acute urinary retention
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
US10532081B2
(en)
|
2016-09-07 |
2020-01-14 |
Nymox Corporation |
Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
|
US11136409B2
(en)
|
2016-09-20 |
2021-10-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
|
TW201815766A
(zh)
|
2016-09-22 |
2018-05-01 |
美商普雷辛肯公司 |
用於ido及tdo調節之化合物及方法以及其適應症
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
CA3047580A1
(en)
|
2016-12-23 |
2018-07-26 |
Plexxikon Inc. |
Compounds and methods for cdk8 modulation and indications therefor
|
EP3634496A4
(de)
|
2017-06-06 |
2021-09-08 |
Dana-Farber Cancer Institute, Inc. |
Verfahren zur sensibilisierung von krebszellen gegen t-zell-vermittelte abtötung mittels modulierung von molekularen signalwegen
|
US10428067B2
(en)
|
2017-06-07 |
2019-10-01 |
Plexxikon Inc. |
Compounds and methods for kinase modulation
|
WO2019108777A1
(en)
|
2017-11-29 |
2019-06-06 |
Research Development Foundation |
Elimination of proliferating cells from stem cell-derived grafts
|
JP2021506267A
(ja)
|
2017-12-13 |
2021-02-22 |
ジーンメディスン・カンパニー・リミテッド |
組換えアデノウイルスおよびこれを含む幹細胞
|
EP3810189A1
(de)
|
2018-06-19 |
2021-04-28 |
Armo Biosciences, Inc. |
Zusammensetzungen und verfahren zur verwendung von il-10-wirkstoffen in verbindung mit einer chimären antigen-rezeptor-zelltherapie
|
WO2020097193A1
(en)
|
2018-11-06 |
2020-05-14 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
WO2020094764A1
(en)
|
2018-11-07 |
2020-05-14 |
Consejo Superior De Investigaciones Científicas (Csic) |
Double and inducible suicide gene construct and its use in gene therapy
|
US11013764B2
(en)
|
2019-04-30 |
2021-05-25 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
WO2020223121A1
(en)
|
2019-04-30 |
2020-11-05 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
JP2022546592A
(ja)
|
2019-09-03 |
2022-11-04 |
マイエロイド・セラピューティクス,インコーポレーテッド |
ゲノム組込みのための方法および組成物
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
CA3166420A1
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Il2 orthologs and methods of use
|
US20230272090A1
(en)
|
2020-08-05 |
2023-08-31 |
Sandro Vivona |
Il2rb binding molecules and methods of use
|
JP2023536654A
(ja)
|
2020-08-05 |
2023-08-28 |
シンセカイン インコーポレイテッド |
IL10Ra結合分子および使用方法
|
EP4192877A1
(de)
|
2020-08-05 |
2023-06-14 |
Synthekine, Inc. |
Synthetische il2rb/il2rg-zytokine
|
JP2023536652A
(ja)
|
2020-08-05 |
2023-08-28 |
シンセカイン インコーポレイテッド |
IL27Rα結合分子および使用方法
|
AU2021336570A1
(en)
|
2020-09-02 |
2023-02-09 |
Fredrik JOHANSSON SWARTLING |
Predicting cancer relapse and treatment of cancer diseases
|
WO2022086852A2
(en)
|
2020-10-19 |
2022-04-28 |
Dana-Farber Cancer Institute, Inc. |
Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
|
KR20230133837A
(ko)
|
2020-11-04 |
2023-09-19 |
마이얼로이드 테라퓨틱스, 인크. |
조작된 키메라 융합 단백질 조성물 및 그의 사용 방법
|
US20240024474A1
(en)
|
2020-11-13 |
2024-01-25 |
David Avigan |
Personalized fusion cell vaccines
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
WO2023158732A1
(en)
|
2022-02-16 |
2023-08-24 |
Dana-Farber Cancer Institute, Inc. |
Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
|